The Board of Directors at its meeting held today i.e., May 07, 2026 has recommended the final dividend of Rs. 7 per equity share.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies' Board meeting on May 7, 2026 approved multiple items including a final dividend of Rs. 7 per share (total FY26 dividend Rs. 9.33 per share post-bonus adjustment). Two Non-Executive Non-Independent Directors - Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah - resigned citing pre-occupation. Two new Additional Directors, Mr. Uday Patel Kadam and Mr. Gaurav Verma, were appointed. The CEO Mr. Rahul Franklin Guha was re-appointed for 5 years from May 2027. Statutory auditors changed from M S K A & Associates LLP to Price Waterhouse Chartered Accountants LLP for a 5-year term. The company also approved investing up to Rs. 5.5 crore in its wholly-owned subsidiary Think Health Diagnostics Private Limited and amendments to its Memorandum of Association to expand business scope.
The resignation of two board directors and appointment of two new directors indicates significant board composition changes. The dividend recommendation of Rs. 9.33 per share for FY26 signals financial health and shareholder-friendly policies. The auditor change and MOA amendments reflect governance and expansion initiatives.